Helius Medical TechnologiesNASDAQ: HSDT

-- Inclusion of the top neurorehabilitation centers REHABOLOGYM, Neurology Center of New England, and MGH Institute of Health Professions completes site participation enrollment for the U.S. registrational program in stroke -- -- In Canada, an additional study on the use of Portable Neuromodulation Stimulator (PoNS®) Therapy to treat stroke has started to support Canadian reimbursement and U.S. approval for stroke --

Helius Medical Technologies, Inc. (NASDAQ:HSDT) Q1 2024 Results Conference Call on May 13, 2024 at 4:30 PM ET. Company Participants include Michelle Bilski from Investor Relations-In-Site Communications, Dane Andreeff - President and CEO, and Jeff Mathiesen - CFO. Conference Call Participants include Nicholas Sherwood from Maxim Group. Operator welcomes everyone to the Helius Medical Technologies First Quarter 2024 Earnings Conference Call.

Helius Medical Technology (NASDAQ: HSDT) shares are surging on Friday with high trading volume, as over 3.5 million shares of HSDT stock have been traded so far.

Helius Medical Technologies, Inc. (HSDT) Q4 2023 Earnings Call Transcript

NEWTOWN, Pa., March 15, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its fourth quarter and full year 2023 financial results on Thursday, March 28, 2024, after the market closes.

NEWTOWN, Pa., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Dane Andreeff, President and Chief Executive Officer, will present at the NobleCon 19th Annual Emerging Growth Equity Conference as follows:

Helius Medical Technologies, Inc (NASDAQ:HSDT ) Q3 2023 Earnings Call Transcript November 9, 2023 4:30 PM ET Company Participants Michelle Gable Bilski - In-Site Communications, IR Dane Andreeff - President and CEO Jeffrey Mathiesen - CFO Conference Call Participants Nicholas Sherwood - Maxim Group Jonathan Aschoff - ROTH MKM Operator Good day, everyone. My name is Chelsea, and I will be your conference operator.

-- Expects to report Q3 revenues in range of $140 - $150 thousand, reflecting the expected decrease in U.S. sales with the conclusion of the Patient Therapy Access Program (PTAP) on June 30, 2023 -- -- Expects to report approximately $7.0 million in cash, cash equivalents and proceeds receivable from warrant exercises, extending cash runway into Q2 2024 -- -- Expects to report cash used in operating activities for the first nine months of 2023 ranging from $8.3 - $8.4 million, and for Q3 $2.4 - $2.5 million, reflecting continued focus on cash management --

-- Presentation to educate on Portable Neuromodulation Stimulator (PoNS®) Therapy, highlighting the differentiation from other neuromodulation technologies, and the science behind its effectiveness, clinical data, safety profile -- -- Forum brings together world experts from the core disciplines of clinical neurosciences and rehabilitation --